MedTrace Logo

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2010-05-31

No results posted yet for this study

Summary

The objective of this study is to determine whether there is a relationship between interferon-gamma levels and the incidence of viral respiratory infections in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care (nasal steroids, antihistamines) over a 1-year period. The hypotheses to be tested are 1) interferon-gamma levels will be significantly increased 3, 6, 9 and 12 months in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care, 2) the incidence of viral respiratory infections will be reduced at 3, 6, 9 and 12 months in allergic children treated with allergy immunotherapy as compared to those treated with standard medical care.

Conditions

  • Allergy
  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis

Sponsors & Collaborators

  • Pennsylvania Allergy and Asthma Research Foundation

    collaborator UNKNOWN

  • West Penn Allegheny Health System

    lead OTHER

Principal Investigators

  • Deborah Gentile, MD · West Penn Allegheny Health System

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405899 on ClinicalTrials.gov